Open to Accrual
January 11, 2022
To determine if the addition of OBP-301to chemoradiation with carboplatin/paclitaxel is safe.
Patients with pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) and are not candidates for surgery, but are candidates for chemoradiation. Gastroesophageal junction tumors must be Siewert Type I/II.
NRG-GI007 Staff Educational Materials for OBP-301, version date March 8, 2022
NRG-GI007 Endoscopy Training - June 10, 2020
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.